Epithelial Ovarian Cancer-Induced Angiogenic Phenotype of Human Omental Microvascular Endothelial Cells May Occur Independently of VEGF Signaling  by Winiarski, Boleslaw K. et al.
Epithelial Ovarian Cancer–
Induced Angiogenic
Phenotype of Human Omental
Microvascular Endothelial Cells
May Occur Independently
of VEGF Signaling1,2
Boleslaw K. Winiarski*, Katarzyna I. Wolanska*,
Srijana Rai*, Tahanver Ahmed*,
Nigel Acheson*,†, Nicholas J. Gutowski*,†
and Jacqueline L. Whatmore*
*Institute of Biomedical and Clinical Science, University of
Exeter Medical School, Exeter, Devon, United Kingdom;
†Royal Devon and Exeter NHS Foundation Trust, Exeter,
United Kingdom
Abstract
Epithelial ovarian cancer (EOC) metastasizes transcoelomically to the peritoneum and omentum, and despite surgery
and chemotherapy, recurrent disease is likely. Metastasis requires the induction of proangiogenic changes in the
omental microenvironment and EOC-induced omental angiogenesis is currently a key therapeutic target. In particular,
antiangiogenic therapies targeting the vascular endothelial growth factor A (VEGFA) pathway are commonly used,
although, with limited effects. Here, using human omental microvascular endothelial cells (HOMECs) and ovarian
cancer cell lines as an in vitromodel, we show that factors secreted from EOC cells increased proliferation, migration,
and tube-like structure formation in HOMECs. However, EOC-induced angiogenic tube-like formation and migration
were unaffected by inhibition of tyrosine kinase activity of VEGF receptors 1 and 2 (Semaxanib; SU5416) or neutral-
ization of VEGFA (neutralizing anti-VEGFA antibody), although VEGFA165-induced HOMEC migration and tube-like
structure formation were abolished. Proteomic investigation of the EOC secretome identified several alternative
angiogenesis-related proteins. We screened these for their ability to induce an angiogenic phenotype in HOMECs,
i.e., proliferation, migration, and tube-like structure formation. Hepatocyte growth factor (HGF) and insulin-like growth
factor binding protein 7 (IGFBP-7) increased all three parameters, and cathepsin L (CL) increased migration and tubule
formation. Further investigation confirmed expression of the HGF receptor c-Met in HOMECs. HGF- and EOC-induced
proliferation and angiogenic tube structure formation were blocked by the c-Met inhibitor PF04217903. Our results
highlight key alternative angiogenic mediators for metastatic EOC, namely, HGF, CL, and IGFBP-7, suggesting that
effective antiangiogenic therapeutic strategies for this disease require inhibition of multiple angiogenic pathways.
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Introduction
Epithelial ovarian cancer (EOC) is the most lethal of all gynecological
cancers. Symptoms are often vague, leading to advanced disease with
widespread metastases at diagnosis. Although EOC can metastasize
through the hematogenous, lymphatic, or transcoelomic route, it
is the latter that most commonly leads to metastases, with spread
occurring through peritoneal and omental dissemination [1]. Although
the exact mechanisms of metastasis formation by this route are not
fully understood, it is widely accepted that implantation of metastatic
EOC cells on the peritoneal organs is followed by the induction of
angiogenesis in the host organ, which facilitates metastatic cancer
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growth. Integral to this process is the “switch” of local microvascular
endothelial cells (ECs) to an activated phenotype that supports
tumor angiogenesis.
One of the major organs susceptible to transcoelomic metastatic
spread of EOC is the omentum. The observation that vascular endo-
thelial growth factor A (VEGFA) secretion is upregulated in EOCs
suggested a role for this protein in omental metastasis [2,3] and
prompted the investigation of anti-VEGFA therapy in clinical trials
for patients with gynecological cancers [4]. However, to date, the most
studied therapy, bevacizumab (anti-VEGFA monoclonal antibody),
has shown little efficacy in patients with ovarian cancer, suggesting a
complex metastatic pathway involving mediators other than VEGF
alone. Therefore, an understanding of the proangiogenic signaling net-
works activated in the omental microvasculature during suppression of
the VEGFA pathways in ovarian cancer is necessary to tailor accurate
antiangiogenic therapy to this specific tumor type.
It is likely that the omental metastatic spread of EOC is driven,
at least partially, by the intraperitoneal environment that constitutes
a dynamic reservoir of growth stimulators and prosurvival factors.
However, local manipulation of the microvasculature at the site of
implantation by factors locally secreted by the migrant EOC cells is
also likely to play a key role in the initiation and progression of the
angiogenic process. Indeed, both primary and metastasized ovarian
tumor cells are known to express and/or secrete a range of key pro-
angiogenic proteins, including various forms of VEGFs, angiopoietin-2,
basic fibroblast growth factor (bFGF), hypoxia-inducible factor 1,
and heparin-binding epidermal growth factor–like growth factor, as
well as cytokines involved in tumor immunosuppression and metastatic
progression such as interleukins 6 and 8 and transforming growth
factor–β1 (TGF-β1) [5–9]. It is now recognized that the EOC meta-
static cascade also involves proteases, and proteins such matrix metallo-
proteinases (MMPs) and cathepsins have been implicated [10–12].
However, currently the main clinical focus is on manipulating the metas-
tasizing ovarian cancer cells rather than studying the proangiogenic
responses they initiate in their target microvasculature.
Here, we tested the hypothesis that EOC cells secrete an array of
factors that facilitate angiogenesis in the microvasculature, specifically
ECs, of the omentum during transcoelomic metastasis. It is now well
recognized that ECs from different vascular beds display considerable
phenotypic heterogeneity that is reflected not only in their morphology
but also in their proteome and cellular responses. It is therefore essential
to study ECs from relevant vascular beds when attempting to draw
disease-specific conclusions. We have previously published a technique
for isolating human omental microvascular ECs (HOMECs) [13].
In this report, we use these cells to examine the influence of poten-
tial angiogenesis-associated proteins identified in EOC secretome on
HOMEC phenotype. We demonstrate that ovarian cancer cells induce
HOMEC proliferation, migration, and tube-like structure formation.
However, inhibition of VEGFA signaling either by blocking the ac-
tivity of the VEGF receptors 1 and 2 (VEGFR1/2; using SU5416)
or by anti-VEGFA neutralizing antibody had no inhibitory effect on
ovarian cancer cell–induced HOMEC migration and tube-like struc-
ture formation. These data strongly suggest the involvement of factors
other than VEGFA in the proangiogenic activation of HOMECs when
the VEGFA-VEGFR(s) pathway is disrupted. Using a range of pro-
teomic techniques, we have identified several other potential EOC-
secreted proteins that influence the overall proangiogenic cellular
responses of HOMECs including hepatocyte growth factor (HGF),
cathepsin D (CD), cathepsin L (CL), and insulin-like growth factor
binding proteins (IGFBPs). Furthermore, we have shown that the
HGF receptor c-Met is highly expressed on HOMECs and that
c-Met inhibition by an ATP-competitive inhibitor of c-Met kinase
(PF04217903) prevented the induction of the HOMEC angiogenic
phenotype. Clinically, the action of alternative angiogenic activators
such as those identified could mediate HOMEC angiogenic responses
even in the presence of VEGF pathway inhibition, highlighting a po-
tential therapeutic strategy to circumvent the ineffectiveness of anti-
VEGF therapies in metastatic ovarian cancer.
Materials and Methods
Detailed reagents and equipment are listed in the Supplementary
Materials and Methods section. For abbreviations, see Figure W1.
All experiments were performed with at least two separate isolations
of HOMECs.
Cell Culture and Collection of Conditioned Medium
Nonmalignant omental tissue samples were collected from pa-
tients at the Royal Devon and Exeter NHS Foundation Trust (Exeter,
United Kingdom) with ethical approval and informed written consent.
HOMECs were isolated and cultured as previously described [13].
Ovarian cancer cell lines, SKOV3 and A2780, and human dermal
fibroblasts (HDFs) were purchased from the European Collection of
Cell Cultures (ECACC; Salisbury, United Kingdom) and PromoCell
(Heidelberg, Germany), respectively. Cancer cell lines were cultured
in RPMI 1640 supplemented with gentamicin (50 μg/ml) and 10%
(vol/vol) FBS and HDFs in fibroblast growth medium. HOMECs
were incubated overnight in growth factor (GF)–deprivedMV2medium
before treatments [2% FCS (vol/vol) only]. Collection of tumor and
endothelial conditioned media (CM) is described in the Supplementary
Materials and Methods section.
Proliferation, Migration, and Fibrin Matrix/Geltrex Tube
Formation Assays
For assay details, see Table W1.
Proliferation was assessed using the water soluble tetrazolium salt-1
(WST-1) assay in 96-well plates. HOMECs were incubated overnight
in GF-deprived MV2 medium before treatment. After times indicated,
WST-1 reagent was added in a 1:10 dilution to the assay medium for
a 2-hour incubation and absorbance was measured against the blank
on a microplate reader.
The ThinCert migration assay was carried out according to the
manufacturer’s protocol, with minor changes. SKOV3 and A2780
cells and HDFs were plated on the bottom of a 24-well plate. After
24 hours, HOMECs were seeded into the inserts and the assay was
assembled. Some wells with cancer cells were supplemented with
neutralizing anti-VEGFA antibody (500 ng/ml), and some with
SU5416 (10 μM). The concentration of anti-VEGFA antibody required
to effectively neutralize VEGFA secreted by SKOV3 and A2780 cancer
cells over 72 hours was empirically established before the assay (data
not shown). Control wells contained no cells. After a 24-hour in-
cubation at 37°C, migrated cells were labeled with calcein AM and the
inserts were transferred to a fresh 24-well plate containing prewarmed
trypsin for incubation with shaking. Detached, migrated HOMECs
were allowed to settle, and the fluorescent signal was measured on a
plate reader.
The Oris Cell migration assay was carried out according to the
manufacturer’s recommendations in a 96-well plate. Briefly, HOMECs
were incubated overnight in GF-deprived MV2 medium before treat-
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ments. The assay medium was supplemented with different proteins
(as indicated), SU5416 (10 μM), or with fractions of CM from SKOV3
cells (TCM) or A2780 cells (TCMA; see Fast Protein Liquid Chro-
matography section). Controls included GF-deprived MV2 medium.
After 24 or 48 hours at 37°C, the detection mask was attached to
the bottom of the plate, and calcein AM–labeled, migrated HOMECs
were quantified using a fluorescent plate reader.
Two tube-forming assays were used. Initial studies were carried out
using a fibrin matrix assay (indirect co-culture contact through com-
mon medium) as previously described [14]. HOMECs were seeded
onto fibrin matrices in 10-mm diameter rings or on matrices prepared
in 24-well plates and incubated overnight in GF-deprived MV2 me-
dium. For co-culture experiments, ovarian cancer cells (SKOV3 and
A2780) were plated onto the bottom of the wells (around the rings
containing the matrices) and incubated for 4 hours until attached.
Fresh GF-deprived MV2 medium was added (to cover the wells above
the levels of the rings) either alone (control) or supplemented with
VEGFA165 (positive control) or cancer-secreted proteins (including
40 ng/ml CL, 50 ng/ml HGF, and 50 ng/ml IGFBP-7). SU5416
(Semaxanib) was included in wells with inhibitory treatments. After
72 hours at 37°C, tubule structure formation was analyzed using
bright-field microscopy or fluorescent microscopy for cells labeled with
calcein AM. ImageJ software was used for quantification. The results
are presented as a percentage of control (tube-like structure index).
Further studies used a reduced GF basement membrane extract
(Geltrex) tube formation assay carried out in 96-well microplates with
50 μl of Geltrex per well. For co-culture experiments, ovarian cancer
cells (A2780) were mixed with Geltrex before loading into wells.
Geltrex was allowed to gel for 30 minutes at 37°C, and then calcein
AM–labeled HOMECs were seeded onto matrices. Fresh GF-deprived
MV2 medium (100 μl/well) was added to control and co-culture con-
trol wells. Assay medium was supplemented with HGF (50 ng/ml) ±
PF04217903 (20 nM) or SU5416 (10 μM) as indicated. Assays were
developed for approximately 4 hours in a 37°C humidified incubator
with 5% CO2 followed by fluorescent image acquisition (one picture
per well; total magnification, ×40). Images were then processed
with Corel Paint Shop Pro Photo X2 to ensure a format accessible to
AngioSys software (Caltag Medsystems, Little Balmer, United Kingdom).
Automated quantification was then performed using this software to
determine the number of junctions, number of tubules, and total
tubule length.
Fast Protein Liquid Chromatography
Whole CM from A2780 or SKOV3 cells (15.5 ml) were sequen-
tially fractionated using Amicon Ultra Centrifugal Filter Units (Merck
Millipore, Watford, United Kingdom) with 100,000 and then 10,000
molecular weight (MW) cutoff to produce a 100≤ 10 kDa prefraction
reduced to a volume of ∼400 μl. The concentrated prefractions were
then injected through a 0.5-ml loop onto a Superdex 75 10/300 GL
column (GE Healthcare, Little Chalfont, United Kingdom) of an
ÄKTApurifier. The flow rate was set at 1ml/min, and 1-ml fractions were
collected using basal MV2 medium (for bioassays) or phosphate-
buffered saline (PBS; for ELISA). The relatively large fraction volume
facilitated fraction analysis but reduced protein molecular weight
resolution. Approximate size of unknown proteins in eluted fractions
was assessed by gel filtration molecular weight markers (weight range
of 6500-2,000,000 Da; Sigma, Gillingham, United Kingdom; see
Figure W1A) run through the same system. Fractions were stored at
−80°C until used.
Proteome Profiling (Mass Spectrometry and Antibody Array)
Proteins from a mixed lot of whole CM from SKOV3 cells and
control Dulbecco’s modified Eagle’s medium (DMEM)–Bottenstein-
Sato (BS) medium were affinity purified using StrataClean resin accord-
ing to the manufacturer’s protocol (StrataGene, Wokingham, United
Kingdom). Proteins bound to the beads were sent to Robert Jones and
Agnes Hunt Orthopedic and District Hospital for mass spectrometry
(MS) analysis. For details of MS protocol, see Supplementary Materials
and Methods section.
Protein content of fractions 11 and 12 of A2780 and SKOV3 CM
after fast protein liquid chromatography (FPLC) was analyzed using
the R&D Systems (Abingdon, United Kingdom) Proteome Profiler
antibody array (human angiogenesis) according to the manufacturer’s
protocol. Array data on developed X-ray film were quantitated by densi-
tometry using Quantity One software (Bio-Rad, Hemel Hempstead,
United Kingdom).
Enzyme-Linked Immunosorbent Assays
All ELISAs were carried out according to the manufacturer’s recom-
mendations, except IGFBP-7, which was developed in-house (for
details, see Table W2). For this ELISA, microplates were coated with
capture antibody and incubated overnight at room temperature.
Between all stages of the ELISA, the wells were washed three times
with 0.05% (vol/vol) Tween-20/PBS. Blocking was in 1% (wt/vol)
BSA/PBS. Standards, blanks, detection antibody, and streptavidin-
HRP conjugate were prepared in 0.1% (wt/vol) BSA/PBS. All
samples and standards were added in duplicate followed sequen-
tially by detection antibody, streptavidin-HRP conjugate, 3,3′,5,5′-
tetramethylbenzidine (TMB) substrate, and stop solution as described
in Table W2. Following measurement of absorbance, the standard
curve and concentrations of measured IGFBP-7 were obtained
using data analysis software supplied by BMG Labtech (Aylesbury,
United Kingdom).
Immunocytochemistry
HOMECs were cultured on 2% (wt/vol) gelatin-coated fluorodishes
until confluent. Staining for CD31 and c-Met was performed after
fixation with 4% (wt/vol) paraformaldehyde and blocking with goat
serum (1:10 in PBS). Mixed primary antibodies diluted in PBS were
applied for 60 minutes. Nonspecific staining controls received PBS
alone. After washing, mixed secondary antibodies were applied for
30 minutes. All incubations were performed at room temperature.
Cells were counterstained with 4′,6-diamidino-2-phenylindole (DAPI),
mounted, and analyzed using a fluorescent microscope and imaging
software (Openlab 4.0.4, Corel Paint Shop Pro Photo X2). For proce-
dure and antibody details, see Table W3.
Results
Factors Released from Ovarian Cancer Cells Increase HOMEC
Proliferation, Migration, and Tube-Like Structure Formation
Angiogenesis requires phenotypic changes in normal relatively
quiescent ECs. In tumor-induced angiogenesis, the factors activating
ECs and initiating these cellular changes originate in cancer cells and
tumor-associated cells. Therefore, our initial experiments assessed the
mitogenic, migratory, and angiogenic potential of the total secretome
of ovarian cancer cells on HOMECs using CM or co-culture tech-
niques. CM from two different ovarian cancer cell lines (SKOV3 and
A2780) induced a significant time-dependent increase in proliferation
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of HOMECs (Figure 1A; **P≤ .01 and ***P≤ .001, n = 4). Further-
more, HOMECs actively migrated in response to VEGFA165 or when
co-cultured with SKOV3 and A2780 cells, but this effect was not ob-
served with the normal HDFs (Figure 1, B and C ; **P ≤ .01 and ***P
≤ .001, n = 12). Finally, we showed that HOMEC can undergo VEG-
FA165-induced (positive control) and EOC-mediated tube-like struc-
ture formation in an in vitro tube formation assay (Figure 1E ; *P ≤
.05, **P ≤ .01, and ***P ≤ .001, n = 8-16).
Ovarian Cancer–Mediated Migration and Tube-Like Structure
Formation Is Unaffected by Inhibition of the VEGF Pathway
Given the accepted importance of VEGFA to the angiogenic pro-
cess, we examined whether inhibition of VEGFR1/2 in HOMECs
would alter in vitro tube-like structure formation and migration.
SU5416 is a potent synthetic inhibitor of the tyrosine kinase activity
of VEGFR1/2, previously shown to effectively inhibit VEGFA165-
and placenta growth factor 1 (PlGF-1)–induced autophosphorylation
Figure 1. Ovarian cancer cell secretome increases HOMEC cellular responses and contains a range of potential proangiogenic proteins.
(A) Proliferation of HOMECs treated with CM from SKOV3 and A2780 cells for 24, 48, or 72 hours assessed using theWST-1 assay. Controls
received basal medium only. **P ≤ .01 and ***P ≤ .001 versus control levels (100%). (B) Migration of HOMECs in co-culture with ovarian
cancer cells and HDFs (co-culture control) assessed by the ThinCert migration assay. After 24 hours, fluorescence of migrated cells was
quantified. ***P≤ .001 versus control (100%) and ###P≤ .001 versus HDFs. (C) HOMEC Oris cell migration after 48 hours in the presence
of VEGFA165 (20 ng/ml) ± SU5416 (10 μM). Controls received medium alone. ***P ≤ .001 versus control (100%) and
###P ≤ .001 versus
VEGFA165. (D) Migration of HOMECs in co-culture with ovarian cancer cells ± anti-VEGFA antibody (500 ng/ml) or SU5416 (10 μM)
assessed by the ThinCert migration assay. ***P ≤ .001 versus control (100%), **P ≤ .01 versus control (100%), and NS versus A2780
or SKOV3. (E) VEGF- and EOC cell–induced tube-like structure formation of HOMECs and the effects of the SU5416 inhibitor. HOMECs
were plated onto fibrin matrices and exposed to either VEGFA165 or EOC cells in co-culture ± SU5416 (10 μM). Negative controls received
medium alone. Tube-like structure formation was quantified. *P ≤ .05, **P ≤ .01, and ***P ≤ .001 versus control (100%), ###P ≤ .001
versus VEGF, and NS versus SKOV3/A2780. For A to E, data are presented as means ± SD. P values were calculated by one-way analysis
of variance (ANOVA), followed by Tukey’s post hoc test. (F) Shotgun proteomics of SKOV3 CM by the 4800 MALDI TOF/TOF analyzer.
Significant results were determined by selecting proteins that matched with two or more peptides with total ion CIs of >95%, followed
by a literature search to determine proteins with a possible role in angiogenesis. (G) Analysis of CL, CD, IGFBP-7, and VEGF concentration
in CM from SKOV3 and A2870. Commercially available ELISAs were used for determination of VEGF, CD, and CL concentrations, whereas
the IGFBP-7 ELISA protocol was developed in-house. All experiments were carried out in duplicate on three separate samples. B/D, below
detection limit.
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of both receptors at concentrations ≥0.5 μM [15]. Our previous data
showed that in human umbilical vein ECs (HUVECs) SU5416 abol-
ished VEGFA165-induced in vitro tube-like structure formation at a
concentration of 10 μM [16]. Figure 1 indicates that VEGFA165-
inducedmigration and tube-like structure formation inHOMECswere
significantly inhibited by SU5416 but that EOC-dependent migration
and tube-like structure formation were unaffected by the presence of
the inhibitor (Figure 1, C–E ; ###P ≤ .001, n = 12; **P ≤ .01 and
***P ≤ .001, n = 9; ###P ≤ .001, n = 8-16, respectively). To examine
this further, we investigated whether depletion of VEGFA from the
co-culture system by neutralizing anti-VEGFA antibody influenced
HOMEC migration. VEGFA neutralization had no significant effect
on migration of HOMECs (Figure 1D; NS for SKOV3 + antibody/
SKOV3+ SU5416 andA2780+ antibody/A2780+ SU5416 vs SKOV3
and A2780, respectively). These results indicated that HOMECs can
undergo formation of tubular networks, proliferation, and migration in
response to factors secreted by ovarian cancer cells but that suppression
of the VEGFA pathway was not sufficient to prevent EOC-mediated
HOMEC migration and tube-like structure formation. This suggests
the involvement of additional proangiogenicmediators inEOC-induced
metastatic angiogenic responses in the omental microvasculature.
Ovarian Cancer Cells Secrete a Range of Factors with
a Potential Role in Omental Metastatic Angiogenesis
To further investigate alternative mechanisms for EOC-induced
HOMEC tube-like formation and migration, we initially screened, using
Figure 2. Bioactive effects of fractionated A2780 and SKOV3 CM on HOMEC migration. (A and C) Relative protein content of fractionated
CM from SKOV3 (A) and A2780 (C) assessed by absorbance at 280 nm. A 100≤ 10 kDa prefraction of both tumor CMwas separated by size
exclusion gel filtration, and 1-ml fractions were collected. Distinct protein peaks were observed in both profiles. (B and D) Fractions 11 and
12 of CM from SKOV3 (B) and A2780 (D) obtained by FPLC increase HOMEC migration. The bioactivity of protein-rich fractions (11 and 12)
produced by FPLC was assessed in HOMECs using the Oris Cell migration assay. The experiment was performed on three separate cell
isolations in heptaplicate. Data are presented as means ± SD. *P ≤ .05, **P ≤ .05, and ***P < .001 versus control (100%); P values were
calculated by the Mann-Whitney U test.
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MS, whole CM from SKOV3 cells for the presence of angiogenesis-
related proteins. Although the MS search identified a range of proteins
in the CM (see Table W4), only the following three prospective candi-
dates were identified: CD, CL, and IGFBP-7 (Figure 1F). Surprisingly,
no GFs or cytokines were detected using this approach, presumably
due to limitations of MS in identifying proteins in complex mixtures,
such as CM, and instrument limitation. Thus, ELISAs were carried out
to confirm the presence of VEGFA as well as to quantify MS-identified
factors in tumor CMof SKOV3 and A2780 cancer cell lines. Figure 1G
shows the concentrations of VEGFA (mixed isoforms), CD, CL, and
IGFBP-7 in CM from both cancer cell lines. bFGF was not detected
(data not shown). Clearly, concentrations of measured proteins varied
between cancer cell lines, favoring A2780 as a more potent inducer of
HOMEC cellular changes (see Figure 1).
Fractionation of CM from EOC Cells Reveals Specific
Bioactive Fractions that Stimulate HOMEC Migration
Having identified several angiogenesis-related proteins secreted from
EOC cells, we next carried out a series of experiments to examine the
possible presence of additional, previously undetected potential me-
diators. In initial studies, we performed FPLC size exclusion fractiona-
tion of the CM from both cancer cell lines and screened the fractions
for their promigratory bioactivity on HOMECs. Initially, a 100 ≤
10 kDa prefraction was prepared from the CM because most bioactive
factors were likely to be in this size range. SKOV3 and A2780 cells
displayed distinct profiles of secreted factors, although all fractionated
proteins were found in fractions 8 to 21 for both cell lines (Figures 2, A
and C , and W1A). Functional screening of HOMEC migration in
response to these fractions using the Oris cell assay indicated signifi-
cant promigratory biologic activity in fractions 11 and 12 from both
SKOV3 and A2780 cells (Figure 2, B and D; **P ≤ .01, *P ≤ .05,
and ***P < .001, n = 21, respectively). These data suggested that the
key promigratory factors secreted from the EOC cells were enriched
in these fractions, and therefore, the protein content of these fractions
was investigated further to examine 1) whether the proteins already
identified above, i.e., CL, CD, and IGFBP-7, were present in these
fractions and 2) whether additional, as yet unidentified targets could
be discovered.
Bioactive Fractions 11 and 12 Contain Additional Proteins
Able to Influence HOMEC Proliferation and Migration
Two different approaches were undertaken to identify the secreted
proteins in the promigratory fractions of EOC cell CM. Fractions 11
and 12 were firstly analyzed using a Proteome Profiler human angio-
genesis kit. Although this profiler does not include all of the proteins
previously identified, it did confirm the presence of VEGFA in both
fractions of SKOV3 and A2780 EOC cells (Figure 3A). For a full
description of the proteins analyzed and representative images of the
profiler X-ray films, see Supplementary Materials and Methods sec-
tion (Figure W1, B–D). Again, no secreted bFGF was detected. The
presence of CL and CD in the bioactive fractions from both ovarian
cancer cell lines was confirmed by ELISA, although fraction 11 of both
Figure 3. Identification of angiogenesis-associated proteins in fractions 11 and 12 of CM from SKOV3 and A2780 ovarian cancer cells.
(A) Fractions 11 and 12 of both CMwere profiled using a Proteome Profiler antibody array (human angiogenesis). The results were quantified
by densitometric analysis and are presented as a mean of duplicates corresponding to one target protein. Background and adjustment
factors were subtracted, and angiogenesis-associated proteins with values above the adjustment level are shown. (B) CD, CL, and
IGFBP-7 in fractions 11 and 12 of both CM were examined by ELISA because these targets were not included in the antibody array. For
CD and CL, commercially available ELISAs were employed, whereas for IGFBP-7 an in-house ELISA was used. Each ELISA was carried out
in duplicate on two or three separately collected lots of fractions 11 and 12. B/D, below detection limit of ELISA.
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cancer cell lines contained greater concentrations of CD and CL than
fraction 12 (Figure 3B). IGFBP-7 was only detected in fraction 11
of SKOV3 CM. Additionally, both cancer cell lines secreted other
potent modulators of angiogenesis/proliferation, i.e., endocrine gland
derived (EG)-VEGF, HGF, PlGF-1, PDGF-AA, neuregulin 1-β 1
(NRG1-β1), serpin F1 [pigment epithelium-derived factor (PEDF)],
and angiogenin. Interestingly, results indicated distinct qualitative
and quantitative differences between the two cell lines. For instance,
VEGFA and HGF were found in both tumor CM; however, levels of
both were higher in A2780 cells, particularly HGF. Regulators of extra-
cellular matrix (ECM) remodeling, includingMMP8,MMP9, serpin E1
[plasminogen activator inhibitor type 1 (PAI-1)], tissue inhibitor of
metalloproteinases-1 (TIMP-1), and urokinase-type plasminogen activa-
tor (uPA) were also secreted by both ovarian cancer cell types, as were
additional IGFBPs (implicated in vascular repair and homeostasis, cell
proliferation, and apoptosis).
Taken together, these findings indicate that ovarian carcinoma cells
synthesize and secrete a variety of factors that may influence HOMEC
angiogenic phenotype. These include ligands of VEGFRs/neuropilins
(i.e., VEGF and PlGF-1), ligand of c-Met (HGF), proteases (MMP9,
MMP8, and uPA), protease inhibitors (TIMP-1 and serpin E1), chemo-
attractants (CXCL16 and PF4), antiangiogenic factor PEDF, and
IGFBPs (modulators of IGF/insulin signaling).
To examine which of the identified proteins may have been respon-
sible for the original biologic effects of the whole CM, relevant indi-
vidual proteins present in the bioactive fractions were assessed for
their proliferative and migratory potential (Figure 4, A and B). The
results confirmed significant induction of proliferation by HGF and
IGFBP-7 and a weak (borderline) proliferative effect of PlGF-1 on
HOMECs (Figure 4A; *P ≤ .05, **P ≤ .01, and ***P ≤ .001, n =
18-24). Significant migratory effects of CD, CL, IGFBP-7, and HGF
were also detected (Figure 4B; **P ≤ .01 and ***P ≤ .001, n =
15-19). No increase in HOMEC migration by PlGF-1 was observed.
CL, HGF, and IGFBP-7 Induced Tube-Like Structure
Formation in HOMECs
Next, we examined whether the proteins secreted by EOC cells
were able to induce tube-like structure formation in HOMEC. Fig-
ure 4 indicates that CL, HGF, and IGFBP-7 significantly induced
formation of tube-like structures. CL and HGF induced extensive
lacunae formation with cells reorganizing themselves in characteristic
elongated tube-like structures (Figure 4, C and D; ***P ≤ .001, n =
12). IGFBP-7 also displayed angiogenic activity on HOMECs, how-
ever, to a lesser extent (Figure 4, C and D; ***P ≤ .001, n = 12).
This lack of well-defined tube-like structure formation may suggest
that proangiogenic signaling of IGFBP-7 could be involved in the
later stages of angiogenesis. These data suggest that CL, HGF, and
IGBP-7 trigger a proangiogenic phenotype in HOMECs and that
this could occur independently of VEGFA, because none of them
have been reported to directly bind to VEGFRs.
Figure 4. Individual proteins identified in the EOC cell secretome display mitogenic, migratory, and angiogenic activities in HOMECs.
(A) HGF, PlGF-1, and IGFBP-7 increase HOMEC proliferation. HOMECs were treated with HGF (25 ng/ml), PlGF-1 (25 ng/ml), or IGFBP-7
(25 ng/ml) for 72 hours, and proliferation was assessed by the WST-1 assay. Controls received medium alone, *P ≤ .05, **P ≤ .01, and
***P ≤ .001 versus control (100%). (B) HOMEC migration induced by ovarian cancer–secreted proteins. HOMECs were treated with dif-
ferent proteins for 48 hours (CD, 80 ng/ml; CL, 40 ng/ml; MMP9, 40 ng/ml; IGFBP-7, 20 ng/ml; HGF, 25 ng/ml; and PlGF-1, 25 ng/ml),
and migration was assessed using the Oris migration assay. Controls received medium alone, **P ≤ .01 and ***P ≤ .001 versus control
(100%). (C) HGF, CL, and IGFBP-7 induced formation of tube-like structures in HOMECs. HOMECs were seeded onto fibrin matrices in
24-well plates, incubated overnight, and then treated with HGF (50 ng/ml), CL (40 ng/ml), and IGFBP-7 (50 ng/ml). After a maximum of
72 hours, tubule structures were quantified and expressed as a percentage of control, ***P ≤ .001 versus control (100%). For A to C, data
are presented as means ± SD. P values were calculated by one-way ANOVA, followed by Tukey’s post hoc test. (D) Representative images
of the tube-like structure formation assessed in C. HOMECs are labeled with calcein AM for quantitation; original magnification, ×100.
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HOMEC c-Met Inhibition Reduces HGF-Mediated Mitogenic
and Angiogenic Effects
HGF signals through its tyrosine kinase receptor c-Met. Because
HGF was secreted from EOC cells and influenced HOMEC migra-
tion, proliferation, and tube-like structure formation, we investigated
c-Met expression on HOMECs. Figure 5A shows that HOMECs
highly express c-Met along with the endothelial marker CD31. Func-
tional experiments indicated that an ATP-competitive inhibitor of
c-Met kinase, PF04217903, abolished the significant increase in
HOMEC proliferation induced by both HGF and CM from A2780
ovarian cancer cells (Figure 4B; ***P ≤ .001 and ###P ≤ .001, n =
24). Published studies in preclinical models indicate that activation
of alternative angiogenic pathways during anti-VEGFA therapy may
potentially lead to unresponsiveness of the tumors to therapy [17].
Therefore, we further investigated the role of the HGF pathway
by examining whether HGF- and A2780-stimulated HOMEC tube
structure formation could be inhibited by PF04217903. We chose to
study the A2780 EOC cell line because it secretes HGF and VEGF to
a similar extent and, also, does not express c-Met [18], ensuring our
research design would not influence the cancer cells. The data pre-
sented in Figure 5 show that both HGF- and A2780-mediated in vitro
angiogenic changes of HOMECs (number of tubules, total tubule
length, and number of junctions) were reduced to control levels by
PF04217903 (Figure 5, C–E ; ***/###P ≤ .001, **P ≤ .01, and
*/#P ≤ .05, n = 10). Furthermore, lack of antiangiogenic effect of
SU5416 in co-culture with A2780 cells was confirmed.
Discussion
Despite improvements in clinical management, and substantial invest-
ment in clinical trials, the prognosis for patients with ovarian cancer
remains poor. The urgent search for effective treatment has led to trials
of antiangiogenic therapy, with the VEGF-VEGFR axis offering an
attractive target, e.g., VEGF traps, a soluble receptor decoy, small tyro-
sine kinase inhibitors of VEGFRs, and also antibodies (anti-VEGFA or
anti-VEGFRs), particularly bevacizumab [4,19,20]. Despite the poten-
tial benefits of antiangiogenic therapy in EOC trials, results have not
been encouraging, with a range of problems encountered including 1)
Figure 5. Inhibition of c-Met in HOMECs abolishes HGF- and EOC-mediatedmitogenic and angiogenic responses. (A) HOMECs express the
HGF receptor c-Met. HOMECs were co-stained for CD-31 (red) and c-Met (green). Nuclei were stained with DAPI (blue). (a) Membranous
expression of endothelial marker CD31, which coincided with diffused membrane expression of c-Met. (b) Negative control without pri-
mary antibody. Scale bar, 40 μm. (B) Proliferation of HOMECs (48 hours) treated with either HGF or CM from A2780 cells ± the c-Met
inhibitor (PF04217903) assessed using the WST-1 assay. Controls received basal medium only. ###P ≤ .001 versus control levels (100%)
and ***P≤ .001 versusHGForA2780. (C–E) Inhibition ofHGF- andEOC-inducedHOMECtube formation (using basementmembraneextract)
by the c-Met kinase inhibitor (PF04217903; 20 nM). Quantification of number of tubules (C), total tubule length (D), and number of junctions
(E) of HOMEC was performed by AngioSys software. ###P ≤ .001 and #P ≤ .05 versus control levels (100%), ***P ≤ .001, **P ≤ .01, and
*P ≤ .05 versus A2780 or HGF (50 ng/ml). For A to D, data are presented as means ± SD. P values were calculated by one-way ANOVA,
followed by Tukey’s post hoc test.
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small benefits in progression-free survival, 2) numerous adverse effects,
and 3) lack of significant impact on overall survival [20,21].
It is now well recognized that metastasized primary tumor cells secrete
factors that alter their microenvironment and initiate angiogenic
responses in the microvessel endothelium of the host organ, i.e., prolifer-
ation, migration, and ultimately angiogenesis. However, the array of
tumor factors secreted, and EC signaling pathways activated, to achieve
these changes is likely to be highly specific to the tumor type and the
target endothelium, and further complexity might be achieved by ad-
ministration of antiangiogenic therapy. In this study, we specifically
examined the influence of EOC-secreted proteins on phenotypic changes
in the omental microvasculature using an in vitro model of HOMECs
and EOC cells. Initially, we demonstrated that the total secretome of
EOC increased HOMEC proliferation, migration, and tube-like struc-
ture formation. However, investigation of the role of the VEGF-VEGFR
axis showed that although inhibition of the VEGFR1/2 tyrosine kinases
(SU5416) abolished VEGFA165-mediated HOMEC migration and
tube-like structure formation, EOC cell–induced migration and tube-
like structure formation were refractory to such inhibition. Similarly in
the co-culture migration assay EOC-induced HOMEC migration was
not inhibited by the depletion of VEGFA ligand (anti-VEGFA anti-
body). These data strongly imply that EOC cells secrete factors other than
VEGFA that are able to contribute to the induction of a proangiogenic
phenotype in HOMECs during suppression of VEGFA-VEGFR sig-
naling. This perhaps could provide an explanation for the disappointing
outcomes of VEGFA-targeted therapies in EOC. Although a discussion
of EC heterogeneity is not within the remit of this report, it is important
to note that when we carried out identical studies using HUVECs,
VEGFR1/2 inhibition with SU5416 significantly inhibited EOC-
induced tubule formation (data not shown), highlighting the importance
of studying disease-relevant in vitro model systems.
In light of our initial findings, we investigated, using various pro-
teomic approaches, other potential activators secreted by EOC cells that
could induce proangiogenic responses in HOMEC. Interestingly, the
secretomes of A2780 and SKOV3 differed qualitatively and quan-
titatively. This was reflected in their ability to induce HOMEC pro-
liferation, tube-like structure formation, and migration. This may be
explained by the presence of CD133+ cells in the A2870 cell popula-
tion. CD133+ ovarian cells were reported recently and termed cancer-
initiating cells [22]. Of 40 screened ovarian cancer cell lines, 15 were
positive for CD133 expression, with A2780 having strong hetero-
geneous positivity and SKOV3 being negative. The CD133+ A2780
cancer cells exhibited enhanced aggressiveness, closely resembling
metastatic ascites-derived primary ovarian cancer cells, compared to
CD133− A2780 cells. It is now recognized that cancer-initiating
cells produce larger quantities of proangiogenic factors (reviewed in
[23]); therefore, the observed effect of A2780 cells may arise from
the presence of CD133+ A2780 cells in this cancer cell population.
A range of mediators implicated in angiogenesis and antiangiogenic
factors was identified in the secretome of EOC cells. These fell into
several distinct groups: first, regulators of ECM, including proteases
such as MMP8 and MMP9, CD and CL, and uPA, and protease
inhibitors such as TIMP-1 and PAI-1. Because the process of angio-
genesis is characterized by temporal regulation of the equilibrium
between proangiogenic and antiangiogenic factors, the presence of anti-
angiogenic TIMP-1 and PEDF in the EOC CM is not surprising. It
has been reported that the proteases CL and CD have proangiogenic
roles as upstream stimulators of MMP secretion/activation and endo-
thelial migration [24–26]. However, the mechanism involved in
CL-mediated regulation of HOMECmigration and tube-like structure
formation needs further investigation. The presence of MMPs in the
EOC secretome agrees with the general concept of MMP involvement
in cancer-mediated angiogenesis. Specifically, tumor-secreted MMP9,
but not membrane-anchored MMP9, has been implicated in MMP9-
induced tumor angiogenesis, associating with increased VEGFA/
VEGFR2 expression [27].
The second major group of secreted factors identified consisted
of chemokines and GFs, i.e., HGF, VEGFA, PlGF-1 and CXC-
motif, and CC-motif chemokines. We hypothesized that ovarian
cancer cell–derived HGF may be a surrogate proangiogenic factor
since not only has it recently been reported that EC HGF/c-Met
activation promotes tumor angiogenesis in sunitinib-resistant cancers
[28] but also HGF has been implicated in activation of the uPA
receptor (uPAR) pathway. Activation of the uPAR pathway (uPA–
uPAR) has been reported to be a critical step in VEGFA-mediated
angiogenesis in other systems [29]. Because HOMEC tube-like
structure formation and migration can be induced in the presence of
VEGFR inhibition or VEGFA depletion, it is possible that HGF
acts as an alternative activator of the uPAR pathway. Indeed, HGF
has been shown to stimulate the expression of uPA and uPAR in
ECs, promoting their migration and invasiveness [30]. Paradoxically,
PAI-1, a serine protease inhibitor of uPA, which we detected in EOC
CM and which controls uPA-uPAR-plasmin fibrinolysis, has long
been implicated in tumor progression and angiogenesis. Despite illu-
sive mechanisms explaining this phenomenon, a conceptual link sug-
gests that PAI-1 protects ECs from plasmin-induced FasL-mediated
apoptosis [31] and may regulate cellular motility in the surrounding
matrices [32]. Several reports have demonstrated a synergistic effect
of VEGFA165 and either PlGF-1 or HGF on EC survival, chemotaxis,
and angiogenic response [33,34]. In our studies, HGF displayed mi-
totic, chemotactic, and proangiogenic activity on HOMECs, whereas
PlGF-1 only marginally increased HOMEC viability. Furthermore,
we demonstrated that HOMECs strongly express the HGF receptor
c-Met and that c-Met inhibition by PF04217903 is more effective
than standard anti-VEGFA approaches in inhibiting the induction
of HOMEC angiogenic phenotypes. These data again suggest that
HGF could contribute to the EOC-induced proangiogenic HOMEC
responses observed during suppression of the VEGFA-VEGFR axis.
Interestingly, the VEGFA165 and HGF pathways converge down-
stream, activating the same mitogen-activated protein kinases (MAPKs)
and regulating components of cytoskeletal signaling in HUVECs [35].
The putative link between the pathways may be the scaffolding adaptor
proteins Gab1/Gab2, which, upon autophosphorylation, bind to various
Src homology 2 domain–containing transducers, such as protein tyrosine
phosphatase 2, phosphatidylinositol 3-kinases and phospholipase C–γ
[36]. Signal transduction through Gab1/Gab2 is essential in VEGFR2-
mediated MAPK activation, e.g., during angiogenesis, and has recently
also been reported to be downstream of c-Met activation in ECs, again
promoting EC migration and in vitro angiogenic phenotype [37,38].
The observation that chemokines were secreted by EOC contributes
to the growing literature highlighting their role in the proangiogenic
tumor microenvironment. Two of the chemokines identified in the
EOC secretome, PF4 and CXCL16, have been reported to have pro-
angiogenic effects. For instance, tumor-secreted PF4 has been shown to
chemoattract monocytes, neutrophils, activated T cells, natural killer
cells, and fibroblasts [39–41]. Additionally, CXCL16 is strongly mi-
totic for fibroblasts [42] and mediates proliferation and migration of
CXCR6-expressing T cells [43]. Interestingly, it has been reported that
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tumor-associated fibroblasts are able to promote tumor angiogenesis
during inhibition of VEGFA signaling [44].
The third group of factors identified includes the IGFBPs. We
particularly focused on IGFBP-7, which was present in the secretome
of ovarian cancer cells and enhanced HOMEC proliferation, migration,
and tube-like structure formation. Compelling evidence has described
a strong up-regulation of IGFBP-7 in tumor microvasculature and
in vitro capillary tube-like structures [45]. Indeed, IGFBP-7 has recently
been implicated in vascular remodeling through modulation of VEGF
bioavailability and, consequently, vascular patterning [46]. Additionally,
IGFBP-7 induced tube-like structure formation in brain ECs, through
the TGF-1β/ALK5/Smad-2 pathway that is known to be involved in
the regulation of late-stage angiogenesis [47]. This suggests that cancer-
derived IGFBP-7 may contribute toward the formation of functional
nonpermeable tumor vasculature. Another member of the IGFBP fam-
ily identified in the ovarian cancer secretome, IGFBP-2, has been shown
to be associated with cancer-mediated endothelial recruitment through
IGFBP-2/IGF-1/IGF receptor 1 and growth arrest-specific 6/c-mer
proto-oncogene tyrosine kinase (GAS6/MERTK) signaling pathways [48].
To conclude, we have shown that EOC cells secrete an array of
angiogenesis-associated proteins, some of which have profound pro-
angiogenic effects on HOMECs in our in vitro model. Our data sup-
port the hypothesis that EOC-induced omental angiogenesis during
transcoelomic EOC metastasis is driven by the interplay of a range
of proangiogenic factors and that selective disruption of one pathway,
such as during anti-VEGF angiogenic therapy, simply allows the com-
pensatory action of other mediators, e.g., HGF in concert with sup-
portive factors such as cathepsins, chemokines, and IGFBPs (overview
in Figure 6). We believe that our findings may explain the poor effi-
cacy of anti-VEGFA therapies in ovarian cancer and critically highlight
the need to direct antiangiogenic therapies to a broader spectrum of
targets than VEGFA in patients with EOC.
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Figure 6. Potential proangiogenic mechanisms activated in the omentum during transcoelomic EOC metastasis in the presence of anti-
VEGF therapy. Malignant ovarian cancer cells create aggregates as a result of an adaptive metastatic process. Once omental implantation
is established, the micrometastasis starts to secrete proinvasive factors. This leads to a “switching” of the omental microvasculature
toward a proangiogenic phenotype. Secreted proteases and protease inhibitors [MMPs, CD and CL, urokinase (uPA), and PAI-1] interplay
to remodel the ECM allowing the omental ECs to migrate, whereas cancer-derived VEGF and HGF promote vascularization. In the presence
of anti-VEGF therapy (selective inhibition of the VEGFA proangiogenic pathway; represented by SU5416 = Semaxanib), c-Met signaling may
be favored, contributing to the omental angioarchitecture. IGFBP-7 and IGFBP-2 intensify the EC angiogenic response, potentially facilitating
the formation of functional tumor vasculature and EC recruitment, respectively. Furthermore, cancer-secreted chemokines (PF4 and
CXCL16) fuel protumorigenic inflammatory responses in the malignant omentum caused by the migration of distinct proangiogenic cell
populations. Therefore, the presence of anti-VEGF therapy may amplify the impact of alternative proangiogenic transducers, e.g., c-Met
in concert with supportive factors such as cathepsins, MMPs, chemokines, and IGFBPs, possibly explaining the poor efficacy of anti-VEGFA
therapies in ovarian cancer patients with transcoelomic omental metastasis.
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Supplementary Materials and Methods
Reagents and Equipment
The following reagents and equipment were used: ELISA-grade BSA,
human thrombin, EC growth supplement from bovine neural tissue,
CD, CL, MMP9, thrombin, and human plasma (Cat. No. T7009)
from Sigma; DMEM-BS from Gibco (Paisley, United Kingdom);
WST-1 from Roche (Burgess Hill, United Kingdom); PF04217903
and PlGF-1 fromR&DSystems; VEGFA165, Proteome Profiler human
angiogenesis array, CD DuoSet ELISA, and mouse anti-human mono-
clonal IGFBP-7 antibody (clone 192520; capture antibody); streptavidin-
HRP conjugate and ELISA substrate reagent; HDFs, fibroblast growth
medium 2, MV2 endothelial medium kit, and HGF from PromoCell/
PromoKine (Heidelberg, Germany); calcein AM from eBioscience
(Hatfield, United Kingdom); MaxiSorp microplates (Nunc); IGFBP-7,
rabbit polyclonal anti-human IGFBP-7 (biotinylated, detection anti-
body), and CD ELISA from Abcam (Cambridge, United Kingdom);
SKOV3 and A2780 cell lines from the European Collection of Cell
Cultures; ThinCerts (8.0-μm pore diameter) and 24-well plates (Cat.
No. 662638) from Greiner Bio One (Stonehouse, United Kingdom);
Oris Cell migration assay (Cat. No. cma1.101) from Platypus Technol-
ogies (Fitchburg, WI); fibrinogen, human plasma (Cat. No. 341578),
and Amicon centrifugal filters (Cat. No. UFC800324) from Merck
Millipore; anti-VEGFA antibody (Cat. No. 07-1419; recognizes iso-
forms 121, 165, and 189 of VEGFA); VectaSpin Micro (Cat. No.
6835-3001) from GE Healthcare/Whatman.
Preparation and Collection of Tumor and Endothelial CM
For collection of tumor CM, SKOV3 (TCM) or A2780 (TCMA)
cells at 80% to 90% confluence were washed with PBS (×3) and
incubated with chemically defined DMEM-BS medium or MV2
basal medium (1 ml of medium per 9 cm2 of growth area) for 4 or
24 hours at 37°C. Media were then centrifuged (600g, 10 minutes,
4°C) and stored at −80°C for further experiments.
For EC CM, subconfluent cultures of HOMECs were incubated
overnight in GF-deprived MV2 medium, washed with PBS (×3), and
incubated in fresh MV2 basal medium for 24 hours (1 ml of medium
per 9 cm2 of growth area). Some EC CM were supplemented, before
use, with CD (80 ng/ml), CL (40 ng/ml), VEGF165 (20 ng/ml), and
HGF, IGFBP-7, and PlGF-1 at a concentration of 25 ng/ml. EC
CM was processed as for TCM.
Proteome Profiling (MS)
Samples (affinity purified on StrataClean resin) were digested over-
night at 30°C with 20 μl of trypsin (20 μg/ml; Promega) and then
separated by liquid chromatography on an Ultimate 3000 Dionex
system. Each sample was first loaded onto a C18 trapping column
(10 μl) and then eluted onto a C18 analytical column (PepMap).
The column was washed for 5 minutes, and the peptides were then
eluted using a 40-minute MeCN gradient (2%-50%MeCN/H20) with
further elution for 10 minutes at 90% MeCN. Samples were spotted at
10-second intervals using a Probot with α-cyano-4-hydroxycinnamic
acid at 3 mg/ml [70% (wt/vol) MeCN and 0.1% (vol/vol) trifluoro-
acetic acid] at a flow rate of 1.2 μl/min. A 4800 MALDI TOF/TOF
analyzer was used for MS and MS/MS spectra generation. MS settings
are given as follows: mass range set to 700 to 4000 Da; focus mass of
25,000 Da; 50 shots per subspectrum and 1000 total shots per spectrum
(no stop conditions and every subspectrum was accepted); laser intensity
set to 3950. MS/MS settings are given as follows: 50 shots per subspec-
trum and 4000 shots per spectrum; stop conditions: when accumulated
spectrum reaches estimated signal-to-noise ratio (S/N) of 30; minimum
number of peaks above S/N; threshold 10 and subspectra accepted
before S/N test stops 15; every subspectrum was accepted; laser intensity
set to 3950.Maximum of 12 precursors per spot was chosen forMS/MS
(minimum S/N filter 30; weakest precursors acquired first). GPS
explorer software (Applied Biosystems, Paisley, United Kingdom) was
used to search the NCBI database using Mascot server. Significant
results were determined by selecting proteins that matched with two
or more peptides with total ion confidence intervals (CIs) of >95%.
Proliferation, Migration, and Fibrin Matrix/Geltrex Tube
Formation Assays
The parameters used in cell-based assays are shown in Table W1.
Enzyme-Linked Immunosorbent Assays
The parameters used in the final protocol of the in-house developed
IGFBP-7 ELISA are shown in Table W2.
Immunocytochemistry
The antibodies and parameters of immunocytochemistry (ICC)
are shown in Table W3.
Supplementary Results
The FPLC standard curve and the Proteome Profiler (human angio-
genesis kit) analysis of FPLC fractions 11 and 12 of SKOV3 and
A2780 CM are shown in Figure W1. The list of proteins identified
by MS in whole CM from SKOV3 ovarian cancer cell line is shown
in Table W4.
Figure W1. (A) FPLC standard curve. Gel filtration molecular weight markers (weight range of 6500-2,000,000 Da) were injected through
a 0.5-ml loop onto a Superdex 75 10/300 GL column (GE Healthcare) of an ÄKTApurifier. The flow rate was set at 1 ml/min, and fraction
collection volume was set for 1 ml. This system setup provided a range of fractions (8-16) containing proteins of molecular weight
ranging between 200 and 6.5 kDa. Cutoff for collection was set on fraction 21. (B–D) Proteome Profiler (human angiogenesis kit) analysis
of FPLC fractions 11 and 12 of SKOV3 and A2780 CM. (B and C) Representative X-ray films of fractions 11 and 12 of SKOV3 and A2780
obtained after FPLC and used for quantitative densitometric analysis. (D) Table referring human angiogenesis array coordinates to their
full name and abbreviation.
Table W1. Parameters Used in Cell-Based Assays.
Assay Parameters
WST-1 2% gelatin-coated 96-well clear plates (SARSTEDT, Leicester, United Kingdom)
1 × 104 HOMECs per well
150 μl per well of treatment media
Controls and blanks contained GF-deprived MV2 medium or DMEM-BS as appropriate
All media were supplemented with 2% (vol/vol) FBS
Concentrations: VEGF165, 10 ng/ml; HGF, 25 ng/ml; PlGF, 25 ng/ml; IGFBP-7, 25 ng/ml
Microplate reader—FLUOstar Optima
ThinCert migration ThinCerts and 24-well plates (Greiner Bio One)
Medium—MV2 supplemented with 0.1% (wt/vol) BSA
SKOV3, A2780, and HDFs—4 × 104 cells per well in 600 μl of medium
5 × 104 HOMECs per insert in 200 μl of medium
Calcein AM labeling—inserts were transferred into fresh 24-well plate containing 500 μl of calcein AM per well in PBS (5 μM) for 30-minute incubation
Trypsin/PBS (0.125%, vol/vol) for 10 minutes with shaking at 37°C
Microplate reader—PHERAstar Plus was set on FAM optic module with matrix scanning of the wells
Oris Cell migration 2% (wt/vol) gelatin-coated 96-well optical flat-bottom polystyrene black microplate, Nunc (supplied by Fisher Scientific, Loughborough, United Kingdom),
Cat. No. 10281092; the plates
were used with Oris stoppers, tool, and detection mask
4 × 104 HOMECs per well
Assay medium—GF-deprived MV2 medium
Concentrations: CD, 80 ng/ml; CL, 40 ng/ml; MMP9, 40 ng/ml; IGFBP-7, 20 ng/ml; HGF, 25 ng/ml; PlGF-1, 25 ng/ml; and SU5416, 10 μM
Microplate reader—PHERAstar Plus was set on FAM optic module, 20 flashes per cycle, three cycles
Fibrin matrix tube formation assay 12-well plates were used for co-culture assay with rings containing fibrin matrix, whereas 24-well plates were used for HOMEC-only assay
6 × 104 HOMECs per ring in 12-well plates in 2 ml of medium
1.5 × 105 HOMECs per well in 24-well plates in 500 μl of medium
4 × 104 ovarian cancer cells per well
Fibrin matrices—5 mg/ml fibrinogen prepared in MV2 basal medium, 0.6 μl/ml thrombin. Matrices were neutralized for 2 hours with M199 containing
10% (vol/vol) FBS
Concentrations: VEGF165, 20 ng/ml; HGF, 50 ng/ml; CL, 40 ng/ml; IGFBP-7, 50 ng/ml; SU5416, 10 μM
Quantification—three photographs were randomly taken per well, ×4 magnification
Light inverted microscope (Nikon Eclipse TS100); fluorescence microscope (Nikon Eclipse TE2000-U)
Geltrex tube formation assay 96-well clear plates; 50 μl of Geltrex per well
1.3 × 104 HOMECs per well in 100 μl of assay media
3.5 × 104 cancer cells per well in 50 μl of Geltrex
Calcein AM labeling—before HOMEC trypsinization, calcein AM (5 μM) in GF-deprived MV2 medium was added into T25 flasks (2 ml/flask) for
30-minute incubation
Assay development—4 to 4.5 hours
Concentrations: HGF, 20 ng/ml; SU5416, 10 μM; PF04217903, 20 nM
Image acquisition—fluorescence microscope (Nikon Eclipse TE2000-U)
Image processing: Corel Paint Shop Pro Photo X2
Script applied: Image/grayscale
Adjust/brightness/shadow 0, midtone 100, highlights 100
Adjust/brightness/levels 0-60-120
Blur/Gaussian blur 2
Threshold 45 to 50
Adjust/add-removal noise/median filter 5
Adjust/brightness/histogram adjustment 10%
Image/negative image
Quantification—AngioSys software
Script applied: magnification, ×4
ROI (W) 1024 × 768
Threshold: low—0, high—128
Binary/close 2
Clean skeleton—20 pixels
Measure arcs and areas
ROI indicates region of interest.
Table W2. Parameters Used in the Final Protocol of the In-House Developed IGFBP-7 ELISA.
Factor Parameter
1. Plate MaxiSorp microplate, Nunc
2. Capture antibody and blocking 2 μg/ml in PBS (100 μl/well), overnight incubation at room temperature; blocking in 1% (wt/vol) BSA/PBS for 1.5 hours (300 μl/well)
3. Standards Serial dilution of IGFBP-7 starting from 64 to 1 ng/ml (100 μl/well)
4. Detection antibody 200 ng/ml in 0.1% (wt/vol) BSA/PBS for 2 hours (100 μl/well)
5. Streptavidin-HRP conjugate Diluted 1:200 in 0.1% (wt/vol) BSA/PBS for 20 minutes (100 μl/well)
6. Substrate TMB, 15-minute incubation (100 μl/well), stopped with 2N H2SO4
7. Plate reader FLUOstar Optima, 405-nm wavelength
Table W4. List of Proteins Identified by MS in Whole CM from SKOV3 Ovarian Cancer Cell Line.
Protein Name Accession No. Peptide Count Total Ion Score CI (%)
Collagen, type XII, alpha 1 long isoform precursor (Homo sapiens) gi|93141047 25 100
Transferrin (Homo sapiens) gi|37747855 15 100
CD preproprotein (Homo sapiens) gi|4503143 12 100
Actin, gamma 1 propeptide (Homo sapiens) gi|4501887 9 100
Fibronectin precursor (Homo sapiens) gi|31397 9 100
Chain A, crystal structure of human serum albumin gi|3212456 5 100
Chain A, human cystatin C; dimeric form with 3D domain swapping gi|14278690 5 100
Tubulin, beta (Homo sapiens) gi|18088719 6 100
Hypothetical protein DKFZp762H157.1—human (fragment) gi|11276938 7 100
Prosaposin isoform B preproprotein (Homo sapiens) gi|110224476 3 100
Gamma-actin gi|178045 5 100
Chain A, cyclophilin B complexed with [D-(cholinylester)ser8]-cyclosporin gi|1310882 5 100
Enolase 1 (Homo sapiens) gi|4503571 6 100
Heat shock 70 kDa protein 8 isoform 1 (Homo sapiens) gi|5729877 7 99.9999456
Nucleobindin gi|1144316 5 99.9997312
Inter-alpha-trypsin inhibitor heavy chain H2 precursor (ITI heavy chain H2) (Inter-alpha-inhibitor) gi|125000 4 99.9989577
Precursor polypeptide (AA −31 to 1139) (Homo sapiens) gi|37465 7 99.9970998
Chain A, heat shock 70 kDa protein 42 kDa ATPase N-Terminal Domain gi|6729803 5 99.9956003
Cytovillin 2 (Homo sapiens) gi|6457378 5 99.9936111
Unnamed protein product (Homo sapiens) gi|31092 2 99.9794682
Chain D, human insulin hexamers with chain B His mutated to Tyr complexed with phenol gi|5542375 2 99.9778472
Lysyl hydroxylase gi|190074 5 99.9499473
Lactate dehydrogenase A (Homo sapiens) gi|5031857 2 99.8978056
HSPA2 protein (Homo sapiens) gi|23271312 4 99.8127474
IGFBP-7 (Homo sapiens) gi|4504619 2 99.5392899
Chain B, structural properties of the B25tyr-Nme-B26phe insulin mutant gi|61680182 2 99.4710342
GRP78 precursor gi|386758 5 99.4599579
Keratin, type II cytoskeletal 1 (cytokeratin-1) (CK-1) (keratin-1) (K1) (67 kDa cytokeratin) (Hair) gi|1346343 3 99.1674166
Tubulin, alpha 1B (Mus musculus) gi|34740335 2 99.0849868
Alpha 2 globin (Homo sapiens) gi|4504345 2 98.9518396
Unnamed protein product (Homo sapiens) gi|28193108 4 98.9175006
Human type XVIII collagen (Homo sapiens) gi|7717447 3 98.8871732
Heat shock 90 kDa protein 1, beta (Homo sapiens) gi|20149594 4 98.7826162
Cathepsin L1 (Homo sapiens) gi|15214962 2 98.5296258
Nebulin gi|19856971 5 98.5053497
Heat shock protein 90 kDa alpha (cytosolic), class A member 1 isoform 2 (Homo sapiens) gi|154146191 4 98.2034994
Zinc finger protein 294 (Homo sapiens) gi|31657111 3 97.4914229
N2B-Titin isoform (Homo sapiens) gi|17066104 11 97.3725808
Dachsous 2 isoform 1 (Homo sapiens) gi|47059046 2 95.8981126
Calsyntenin 1 isoform 1 (Homo sapiens) gi|57242757 2 94.1388389
Zinc finger, CW type with coiled-coil domain 2 isoform A (Homo sapiens) gi|145553976 2 95.4873905
KIAA1118 protein (Homo sapiens) gi|5689573 2 95.1979418
Titin (Homo sapiens) gi|17066105 14 95.1372018
TGF-β resistance-associated protein TRAG (Homo sapiens) gi|15624075 1 94.1328432
Cytochrome P450-1 gi|181276 2 93.8137474
KIAA0654 protein (Homo sapiens) gi|14133209 3 92.1840194
Protein piccolo (Aczonin) gi|41019528 3 92.1036281
DAP-kinase (Homo sapiens) gi|2094873 3 92.0671793
Galectin 3 binding protein (Homo sapiens) gi|5031863 1 91.9568238
Ciliary rootlet coiled-coil protein-like 2 protein gi|74728061 3 91.0581437
Alpha2-HS glycoprotein (Homo sapiens) gi|2521981 1 90.9128509
Myosin, heavy polypeptide 10, non-muscle (Homo sapiens) gi|41406064 4 89.0608502
Hemoglobin Gower 2 epsilon gi|223114 1 88.5335844
Heterogeneous nuclear ribonucleoprotein A1 (helix-destabilizing protein) (single-strand RNA binding) gi|133254 1 87.8820919
HECT domain containing 3 (Homo sapiens) gi|157738609 4 87.726072
Table W3. Antibodies and Parameters of ICC.
Factors Parameters
No. of HOMECs 1 × 105 cells per dish
Fluorodish World Precision Instruments (Hitchin, United Kingdom), Cat. No. FD3510-100
Coating 2% (wt/vol) gelatin in PBS, Sigma, Cat. No. G9382
Culture parameters 1 hour to allow initial cell attachment followed by an approximately 48-hour incubation until confluent
Media MV2 complete, PromoCell, Cat. No. C-22221
Primary antibodies CD31 (PECAM-1), Sigma, Cat. No. P8590
c-Met, Santa Cruz Biotechnology (Heidelberg, Germany), Cat. No. 8307
Secondary antibodies Goat anti-rabbit whole IgG fluorescein isothiocyanate–conjugated, Sigma, Cat. No. F9887
Goat anti-mouse whole IgG TRITC-conjugated, Sigma, Cat. No. T5393
Dilution of antibodies 200 μl/dish of 1:100 diluted antibodies
Washes Between stages of ICC, cells were washed three times with PBS
Mounting Fluorescent mounting medium, Dako (Ely, United Kingdom), Cat. No. S3023
Table W4. (continued )
Protein Name Accession No. Peptide Count Total Ion Score CI (%)
Nuclear protein GRB1 gi|738309 2 86.4659552
Hypothetical protein (Homo sapiens) gi|31873439 2 84.5322337
Chain B, Lys(B28)pro(B29)-human insulin gi|1633388 1 79.8892837
MLL5 (Homo sapiens) gi|21686536 2 79.7031973
Unnamed protein product (Homo sapiens) gi|18676847 2 78.9414911
Histone H4 gi|223582 2 77.4873035
Beige-like protein; CDC4L protein (Homo sapiens) gi|21434741 2 74.4478392
Agrin precursor (Homo sapiens) gi|2988422 3 73.7319687
Nuclear receptor coactivator CIA (Homo sapiens) gi|11526821 4 73.4277923
NEU1 (Homo sapiens) gi|48145551 2 73.1819288
Stromal interaction molecule 2 precursor gi|17369338 2 73.1819288
Beta tubulin 1, class VI (Homo sapiens) gi|13562114 2 70.7296681
Coiled-coil domain-containing protein 87 gi|74734493 3 70.7296681
Unnamed protein product (Homo sapiens) gi|35883 2 68.9952919
Ankyrin 3 isoform 1 (Homo sapiens) gi|32967601 5 68.491522
Delayed rectifier potassium channel protein (Homo sapiens) gi|1546839 2 66.5475871
Storkhead box 1 (Homo sapiens) gi|63025200 2 66.4704549
Putative (Homo sapiens) gi|553734 1 65.2121454
Protein kinase, cGMP-dependent, type I (Homo sapiens) gi|55962534 1 65.2121454
KIAA1398 protein (Homo sapiens) gi|14133249 2 57.5004774
Signal-regulatory protein gamma isoform 3 precursor (Homo sapiens) gi|94538339 2 64.4018447
KIAA0866 protein (Homo sapiens) gi|27529744 3 62.504115
Hypothetical protein (Homo sapiens) gi|31874832 2 61.0571768
Calpastatin (Homo sapiens) gi|303599 1 60.7872319
KIAA0184 (Homo sapiens) gi|1136428 1 59.8738456
Myosin-14 (myosin heavy chain 14) (myosin heavy chain, non-muscle IIc) (non-muscle myosin heavy chain IIc) (NMHC II-C) gi|71151982 3 58.1222286
Hypothetical protein LOC25912 isoform 1 (Homo sapiens) gi|14149688 1 54.6656276
Putative NADPH oxidase/peroxidase DUOX2 (Homo sapiens) gi|8745533 1 54.6656276
Unnamed protein product (Homo sapiens) gi|7019899 1 54.6656276
CCDC74B protein (Homo sapiens) gi|45709219 1 54.6656276
Unnamed protein product (Homo sapiens) gi|10433917 1 54.6656276
Unnamed protein product (Homo sapiens) gi|34533923 1 54.6656276
DNA-damage inducible protein 2 (Homo sapiens) gi|62955833 1 54.6656276
Slit and Trk-like 3 protein (Homo sapiens) gi|40217820 2 53.8227995
KIAA1352 protein (Homo sapiens) gi|7243085 3 53.8227995
Trichohyalin gi|586120 3 53.3835215
Tyrosine kinase (FER) gi|339715 1 51.6465265
Lasp-1 protein gi|1584035 1 50.9738688
Latent TGF-β binding protein-4 (Homo sapiens) gi|2190402 2 48.8992278
ATG2A protein (Homo sapiens) gi|14250327 3 47.9491715
HKDC1 protein (Homo sapiens) gi|15214423 3 47.8291792
KIAA0723 protein (Homo sapiens) gi|40788339 2 47.4675401
Ninein-like (Homo sapiens) gi|22137756 3 46.8592755
FERM domain containing 1 (Homo sapiens) gi|24432020 2 46.2439208
Beta chain HLA-DQ molecule (Homo sapiens) gi|2654381 1 45.9957883
Cyclin L1 (Homo sapiens) gi|45768720 3 45.8712929
TPA: TPA_exp: rootletin (Homo sapiens) gi|51536418 5 45.6770096
CYFIP1 protein (Homo sapiens) gi|34785311 1 44.6104928
Myeloid/lymphoid or mixed-lineage leukemia protein 2 (ALL1-related protein) gi|37999860 4 44.6104685
Hook-related protein 1 (Homo sapiens) gi|50897852 3 42.0593255
Fms-related tyrosine kinase 4 isoform 2 (Homo sapiens) gi|103472027 2 40.6490581
Beta amyloid peptide precursor gi|226343 4 38.845625
Cadherin-like 23 (Homo sapiens) gi|55962202 3 36.8421306
Unnamed protein product (Homo sapiens) gi|22761565 1 36.4043311
Chain A, crystal structure of human tyrosyl-DNA phosphodiesterase (Tdp1) gi|20150581 2 35.8158741
Hypothetical protein LOC112849 (Homo sapiens) gi|21389361 2 34.4718893
Unnamed protein product (Homo sapiens) gi|34531342 1 34.4718893
Bullous pemphigoid antigen 1, isoforms 1/2/3/4/5/8 (230 kDa bullous pemphigoid antigen) (BPA) (Hemi) gi|27923959 6 34.2367193
FERM domain containing 5 isoform 2 (Homo sapiens) gi|94721308 2 34.0176887
Transcriptional co-repressor Sin3A (Homo sapiens) gi|23397666 4 33.4071479
KIAA0622 protein (Homo sapiens) gi|3327058 2 12.1010892
Dual oxidase (Homo sapiens) gi|7963632 2 30.7487489
SORBS1 protein (Homo sapiens) gi|27503770 2 27.5591281
Golgi antigen gcp372 (Homo sapiens) gi|808869 2 24.2421637
KIAA0522 protein (Homo sapiens) gi|3043568 2 16.4428608
tRNA aspartic acid methyltransferase 1 (Homo sapiens) gi|57471645 1 11.8083339
Hypothetical protein (Homo sapiens) gi|12052734 2 9.54603509
CDC2L5 protein kinase (Homo sapiens) gi|10443222 4 7.43908345
KIAA0551 protein (Homo sapiens) gi|20521083 3 7.22570361
WAP four-disulfide core domain 6 (Homo sapiens) gi|56202734 1 6.58264917
Chloride intracellular channel 1 (Homo sapiens) gi|14251209 3 5.50094383
Hypothetical protein (Homo sapiens) gi|7018446 1 4.62653472
Golgin 97 (Homo sapiens) gi|4504063 1 0.3614002
Insulin-like growth factor-binding protein gi|183116 2 0
Vinculin isoform meta-VCL (Homo sapiens) gi|7669550 2 0
